Scientific Research on Kisolite™
Numerous Papers published by famed MIT Colloid Scientist, Dr. Ernst Hauser, provide clear statements on uses of the mineral from Kisameet Bay for human and animal health.
Hauser’s assertions are now connected to the findings of recent research, now more than 60 years after the introduction of Pharmacology, and with immunology as the subject, we can identify the possibility of being part of solutions for autoimmune diseases.
The targets for products for the commercialization of Kisolite will fall under the guidance of Dr. Neil Branda, 4D Labs, Simon Fraser University.
Research studies on the mineral clay from Kisameet Bay began at MIT in the 1940’s under famed colloid scientist Dr. Ernst Hauser. The principal Paper published by Dr. Hauser is titled “The Kisameet Bay Clay Deposit”.
Read the Early Research conclusions by Dr. Ernst Hauser: MIT PAPER
The findings led to the introduction of Rayvite, which was sold as a curative, was used as a treatment for burns at the Vancouver General Hospital, and sold in Brazil and China as a cosmetic ingredient up until the early 1960’s.
The advent of pharmacology in the 1960’s diminished the use of traditional curatives throughout the world, ushering in a new era of medicine. Since that time the use of antibiotics has become widespread, resulting in concerns regarding antimicrobial resistance.
During the period from 2011 to early 2018 the company was engaged in academic and commercial research. Academic research was funded in part by Mitacs, a national not-for-profit organization that has designed and delivered research and training programs with universities and companies with both federal and provincial governments. Commercial research has been undertaken with private testing laboratories such as Caro Labs, Nutrasource Pharmaceutical and Nutraceutical Services Ltd., BioScreen Testing Services Ltd., Avomeen Analytical Services Ltd. and Nucro-Technics for toxicology and safety studies.
Since November 2018 the company has entered into product development work for formulations of Kisolite that will be specific to target markets, commencing with topical applications for skin conditions. During 2019 product testing will occur at 4D Labs at Simon Fraser University.